Jeremy Watts

Mr. Jeremy Watts

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
JWJeremy Watts
Jeremy Watts
AKAnahita Khojandi
Anahita Khojandi
OSOleg Shylo
Oleg Shylo
RRRitesh Ramdhani
Ritesh Ramdhani
Deep brain stimulation (DBS) is a surgical treatment for advanced Parkinson’s disease (PD) that has undergone technological evolution that parallels an expansion in clinical phenotyping, neurophysiology, and neuroimaging of the disease state. Machine learning (ML) has been successfully used in a wide range of healthcare problems, including DBS. As computational power increases and more data become available, the application of ML in DBS is expected to grow. We review the literature of ML in DBS and discuss future opportunities for such applications. Specifically, we perform a comprehensive review of the literature from PubMed, the Institute for Scientific Information’s Web of Science, Cochrane Database of Systematic Reviews, and Institute of Electrical and Electronics Engineers’ (IEEE) Xplore Digital Library for ML applications in DBS. These studies are broadly placed in the following categories: (1) DBS candidate selection; (2) programming optimization; (3) surgical targeting; and (4) insights into DBS mechanisms. For each category, we provide and contextualize the current body of research and discuss potential future directions for the application of ML in DBS.

31 August 2022 in IEEE Transactions on Intelligent Transportation Systems
Verified
Journal Article
Closed access
JWJeremy Watts
Jeremy Watts
FWFranco Van Wyk
Franco Van Wyk
SRShahrbanoo Rezaei
Shahrbanoo Rezaei
YWYiyang Wang
Yiyang Wang
NMNeda Masoud
Neda Masoud
AKAnahita Khojandi
Anahita Khojandi
To assure the successful operation of connected and automated vehicles, it is critical to detect and isolate anomalous and/or faulty information in a timely manner. To do so, anomaly detection techniques should be implemented in real-time where if the probability of anomalous information exceeds a certain threshold, the information is dealt with accordingly. Traditionally, the threshold for judging whether the data is anomalous is fixed and determined a priori . However, not only does this approach fail to account for the feedback obtained during a trip on the performance of the algorithms, but it also fails to respond to potential changes in rates of anomalies. Hence, it is important to develop an approach that can dynamically alter this threshold in response to exogenous factors to assure reliable and robust system operation. We develop a mathematical framework which utilizes a dynamic threshold for an anomaly classification algorithm in order to maximize the safety of a trip. Specifically, we develop and pair an anomaly classification algorithm based on convolutional neural networks (CNN), with a partially observable Markov decision process (POMDP) model. We solve the resulting POMDP model using the asynchronous advantage actor critic (A3C) deep reinforcement learning algorithm. The prescribed policy determines the anomaly classification threshold in real-time that maximizes the performance. Our numerical experiments show that the POMDP model outperforms state-of-the-art benchmarks, especially under more difficult to detect anomaly profiles.

20 May 2021 in Sensors
Verified
Journal Article
Open access
PDF file
JWJeremy Watts
Jeremy Watts
AKAnahita Khojandi
Anahita Khojandi
RVRama Vasudevan
Rama Vasudevan
FNFatta B. Nahab
Fatta B. Nahab
RRRitesh Ramdhani
Ritesh Ramdhani
Parkinson’s disease medication treatment planning is generally based on subjective data obtained through clinical, physician-patient interactions. The Personal KinetiGraph™ (PKG) and similar wearable sensors have shown promise in enabling objective, continuous remote health monitoring for Parkinson’s patients. In this proof-of-concept study, we propose to use objective sensor data from the PKG and apply machine learning to cluster patients based on levodopa regimens and response. The resulting clusters are then used to enhance treatment planning by providing improved initial treatment estimates to supplement a physician’s initial assessment. We apply k-means clustering to a dataset of within-subject Parkinson’s medication changes—clinically assessed by the MDS-Unified Parkinson’s Disease Rating Scale-III (MDS-UPDRS-III) and the PKG sensor for movement staging. A random forest classification model was then used to predict patients’ cluster allocation based on their respective demographic information, MDS-UPDRS-III scores, and PKG time-series data. Clinically relevant clusters were partitioned by levodopa dose, medication administration frequency, and total levodopa equivalent daily dose—with the PKG providing similar symptomatic assessments to physician MDS-UPDRS-III scores. A random forest classifier trained on demographic information, MDS-UPDRS-III scores, and PKG time-series data was able to accurately classify subjects of the two most demographically similar clusters with an accuracy of 86.9%, an F1 score of 90.7%, and an AUC of 0.871. A model that relied solely on demographic information and PKG time-series data provided the next best performance with an accuracy of 83.8%, an F1 score of 88.5%, and an AUC of 0.831, hence further enabling fully remote assessments. These computational methods demonstrate the feasibility of using sensor-based data to cluster patients based on their medication responses with further potential to assist with medication recommendations.

2 July 2024 in Sensors
Verified
Journal Article
Open access
PDF file
AMAkash Mishra
Akash Mishra
VBVikram Bajaj
Vikram Bajaj
TFToni Fitzpatrick
Toni Fitzpatrick
JWJeremy Watts
Jeremy Watts
AKAnahita Khojandi
Anahita Khojandi
RRRitesh Ramdhani
Ritesh Ramdhani
Introduction: The current approach to assessing bradykinesia in Parkinson’s Disease relies on the Unified Parkinson’s Disease Rating Scale (UPDRS), which is a numeric scale. Inertial sensors offer the ability to probe subcomponents of bradykinesia: motor speed, amplitude, and rhythm. Thus, we sought to investigate the differential effects of high-frequency compared to low-frequency subthalamic nucleus (STN) deep brain stimulation (DBS) on these quantified facets of bradykinesia. Methods: We recruited advanced Parkinson’s Disease subjects with a chronic bilateral subthalamic nucleus (STN) DBS implantation to a single-blind stimulation trial where each combination of medication state (OFF/ON), electrode contacts, and stimulation frequency (60 Hz/180 Hz) was assessed. The Kinesia One sensor system was used to measure upper limb bradykinesia. For each stimulation trial, subjects performed extremity motor tasks. Sensor data were recorded continuously. We identified STN DBS parameters that were associated with improved upper extremity bradykinesia symptoms using a mixed linear regression model. Results: We recruited 22 subjects (6 females) for this study. The 180 Hz STN DBS (compared to the 60 Hz STN DBS) and dopaminergic medications improved all subcomponents of upper extremity bradykinesia (motor speed, amplitude, and rhythm). For the motor rhythm subcomponent of bradykinesia, ventral contacts yielded improved symptom improvement compared to dorsal contacts. Conclusion: The differential impact of high- and low-frequency STN DBS on the symptoms of bradykinesia may advise programming for these patients but warrants further investigation. Wearable sensors represent a valuable addition to the armamentarium that furthers our ability to conduct objective, quantitative clinical assessments.